Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 10/20 | 0.38 |
| ▸ | MC5R | P33032 | 10/20 | 0.38 |
| ▸ | MC3R | P41968 | 10/20 | 0.38 |
| ▸ | MC1R | Q01726 | 10/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.37 |
| ▸ | ITGAV | P06756 | 5/20 | 0.37 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.37 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.37 |
| ▸ | FURIN | P09958 | 1/20 | 0.35 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.35 |
| ▸ | TSLP | Q969D9 | 2/20 | 0.34 |
| ▸ | CTSG | P08311 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21524983 | 0.92 | ITGB3 (0.46) | MC4RMC5RMC3RMC1RITGB3 | |
| SCHEMBL19940190 | 0.90 | ITGB3 (0.37) | MC4RMC5RMC3RMC1RITGB3 | |
| SCHEMBL23966178 | 0.87 | MC4R (0.40) | MC4RMC5RMC3RMC1RITGB3 | |
| SCHEMBL24271698 | 0.84 | ITGB3 (0.44) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL26220061 | 0.82 | ITGB3 (0.47) | MC4RMC5RMC3RMC1RITGB3 | |
| SCHEMBL21524963 | 0.76 | ITGB3 (0.54) | MC4RMC5RMC3RMC1RITGB3 | |
| SCHEMBL26220055 | 0.76 | ITGB3 (0.52) | MC4RMC5RMC3RMC1RITGB3 | |
| SCHEMBL21524976 | 0.75 | ITGB3 (0.52) | MC4RMC5RMC3RMC1RITGB3 | |
| SCHEMBL21524962 | 0.75 | ITGB3 (0.52) | MC4RMC5RMC3RMC1RITGB3 | |
| SCHEMBL21348134 | 0.73 | ITGB3 (0.44) | MC4RMC5RMC3RMC1RITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746124-B2 | Chemoselective thiol-conjugation with alkene or alkyne-phosphonamidates | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2023-09-05 | — | — | US | disclosed |
| US-20220106356-A1 | CHEMOSELECTIVE THIOL-CONJUGATION WITH ALKENE OR ALKYNE-PHOSPHONAMIDATES | FORSCHUNGSVERBUND BERLIN EV (DE) | 2022-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106356-A1 | CHEMOSELECTIVE THIOL-CONJUGATION WITH ALKENE OR ALKYNE-PHOSPHONAMIDATES | PFAS, PHOSPHO1, PNKP | MC4R 4522/4885MC5R 4303/4885MC3R 4480/4885 |
| US-11746124-B2 | Chemoselective thiol-conjugation with alkene or alkyne-phosphonamidates | PFAS, PHOSPHO1, PNKP | MC4R 4522/4885MC5R 4303/4885MC3R 4480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.